ALVO Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of -44.29% compared to Alvotech's net margin of 50.24%. Alvotech's return on equity of -- beat Johnson & Johnson's return on equity of 30.18%.

Alvotech has a consensus price target of $18.00, signalling upside risk potential of 85.95%. On the other hand Johnson & Johnson has an analysts' consensus of $170.19 which suggests that it could grow by 10.36%. Given that Alvotech has higher upside potential than Johnson & Johnson, analysts believe Alvotech is more attractive than Johnson & Johnson.

Alvotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.425, suggesting its less volatile than the S&P 500 by 57.471%.

Alvotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.22% to investors and pays a quarterly dividend of $1.24 per share. Alvotech pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Alvotech quarterly revenues are $151.2M, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Alvotech's net income of -$67M is lower than Johnson & Johnson's net income of $11B. Notably, Alvotech's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 17.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alvotech is 5.30x versus 4.19x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -44.29% compared to Alvotech's net margin of 26.7%. Alvotech's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Alvotech has a consensus price target of $18.00, signalling upside risk potential of 85.95%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $796.67 which suggests that it could grow by 51.6%. Given that Alvotech has higher upside potential than Regeneron Pharmaceuticals, analysts believe Alvotech is more attractive than Regeneron Pharmaceuticals.

Alvotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.331%.

Alvotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.17% to investors and pays a quarterly dividend of $0.88 per share. Alvotech pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Alvotech quarterly revenues are $151.2M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Alvotech's net income of -$67M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Alvotech's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 13.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alvotech is 5.30x versus 4.28x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Teva Pharmaceutical Industries has a net margin of -44.29% compared to Alvotech's net margin of 5.5%. Alvotech's return on equity of -- beat Teva Pharmaceutical Industries's return on equity of -19.8%.

Alvotech has a consensus price target of $18.00, signalling upside risk potential of 85.95%. On the other hand Teva Pharmaceutical Industries has an analysts' consensus of $22.88 which suggests that it could grow by 33.69%. Given that Alvotech has higher upside potential than Teva Pharmaceutical Industries, analysts believe Alvotech is more attractive than Teva Pharmaceutical Industries.

Alvotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Teva Pharmaceutical Industries has a beta of 0.624, suggesting its less volatile than the S&P 500 by 37.582%.

Alvotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Teva Pharmaceutical Industries offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alvotech pays -- of its earnings as a dividend. Teva Pharmaceutical Industries pays out -- of its earnings as a dividend.

Alvotech quarterly revenues are $151.2M, which are smaller than Teva Pharmaceutical Industries quarterly revenues of $3.9B. Alvotech's net income of -$67M is lower than Teva Pharmaceutical Industries's net income of $214M. Notably, Alvotech's price-to-earnings ratio is -- while Teva Pharmaceutical Industries's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alvotech is 5.30x versus 1.16x for Teva Pharmaceutical Industries. Usually stocks with elevated PS ratios are considered overvalued.